Skip to main content
Top
Published in: BMC Nephrology 1/2020

01-12-2020 | Alport Syndrome | Research article

An overview of the multi-pronged approach in the diagnosis of Alport syndrome for 22 children in Northeast China

Authors: Li Zhang, Bai-chao Sun, Bing-gang Zhao, Qing-shan Ma

Published in: BMC Nephrology | Issue 1/2020

Login to get access

Abstract

Background

Alport syndrome (AS) is a kind of progressive hereditary nephritis induced by mutations of different genes that encode collagen IV. The affected individuals usually develop hematuria during childhood, accompanying with gradual deterioration of renal functions. In this study, the multi-pronged approach was employed to improve the diagnosis of AS.

Methods

Twenty-two children were diagnosed and treated at the Department of Pediatric Nephrology of Jilin University First Hospital between January 2017 and January 2020 using the multi-pronged approach. The following information was collected from patients, including age of onset, age at diagnosis, clinical manifestations, family history, renal pathology and genotype.

Results

All these 22 children were diagnosed with Alport syndrome according to the diagnostic criteria formulated by the Japanese Society of Nephrology (2015), among them, only 13 children met the diagnostic criteria released in 1988. All the 22 patients presented with hematuria, and proteinuria to varying degrees was observed in some patients. Three children suffered from hearing loss, but no child in the cohort had any visual problem or renal failure. Meanwhile, five patients were estimated to be at Stage 2, whereas the remaining 17 cases were at Stage 0. Renal biopsies were performed in 18 patients, including 14 showing glomerular basement membranes (GBM)-specific abnormalities. Moreover, 13 children were detected with mutations of genes encoding collagen IV.

Conclusions

The multi-pronged approach helps to improve the diagnosis of AS. Most patients do not have renal failure during childhood, but close assessment and monitoring are necessary. Also, the advancements in treatment are reviewed.
Literature
2.
go back to reference Kashtan CE, Segal Y. Genetic disorders of glomerular basement membranes. Nephron Clin Pract. 2011;118:c9–c18.CrossRef Kashtan CE, Segal Y. Genetic disorders of glomerular basement membranes. Nephron Clin Pract. 2011;118:c9–c18.CrossRef
5.
go back to reference Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020:1–12. https://doi.org/10.1093/ckj/sfz176. Matthaiou A, Poulli T, Deltas C. Prevalence of clinical, pathological and molecular features of glomerular basement membrane nephropathy caused by COL4A3 or COL4A4 mutations: a systematic review. Clin Kidney J. 2020:1–12. https://​doi.​org/​10.​1093/​ckj/​sfz176.
7.
go back to reference Rumpelt HJ, Langer KH, Schärer K, et al. Split and extremely thin glomerular basement membranes in hereditary nephropathy (Alport's syndrome). Virchows Archiv A. 1974;364(3):225.CrossRef Rumpelt HJ, Langer KH, Schärer K, et al. Split and extremely thin glomerular basement membranes in hereditary nephropathy (Alport's syndrome). Virchows Archiv A. 1974;364(3):225.CrossRef
8.
go back to reference Massella L, Gangemi C, Giannakakis K, et al. Prognostic Value of Glomerular Collagen IV Immunofluorescence Studies in Male Patients with X-Linked Alport Syndrome. Clin J Am Soc Nephrol Cjasn. 2013;8(5):749.CrossRef Massella L, Gangemi C, Giannakakis K, et al. Prognostic Value of Glomerular Collagen IV Immunofluorescence Studies in Male Patients with X-Linked Alport Syndrome. Clin J Am Soc Nephrol Cjasn. 2013;8(5):749.CrossRef
9.
go back to reference Hanson H, Storey H, Pagan J, et al. The value of clinical criteria in identifying patients with X-linked Alport syndrome. Clin J Am Soc Nephrol. 2011;6(1):198–203.CrossRef Hanson H, Storey H, Pagan J, et al. The value of clinical criteria in identifying patients with X-linked Alport syndrome. Clin J Am Soc Nephrol. 2011;6(1):198–203.CrossRef
10.
go back to reference Nakanishi K, Yoshikawa N. Alport syndrome. Nihon Jinzo Gakkai Shi. 2015;57(4):736–42.PubMed Nakanishi K, Yoshikawa N. Alport syndrome. Nihon Jinzo Gakkai Shi. 2015;57(4):736–42.PubMed
11.
go back to reference Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M. Genetics of classic Alport's syndrome. Lancet. 1988;2:1005–7.CrossRef Flinter FA, Cameron JS, Chantler C, Houston I, Bobrow M. Genetics of classic Alport's syndrome. Lancet. 1988;2:1005–7.CrossRef
17.
go back to reference Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57–63.CrossRef Charbit M, Gubler MC, Dechaux M, et al. Cyclosporin therapy in patients with Alport syndrome. Pediatr Nephrol. 2007;22(1):57–63.CrossRef
20.
go back to reference Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy. Kidney Int. 2003;64(4):1169–78.CrossRef Savige J, Rana K, Tonna S, et al. Thin basement membrane nephropathy. Kidney Int. 2003;64(4):1169–78.CrossRef
21.
go back to reference Endreffy E, Ondrik Z, Kemény E, et al. IV-es típusú kollagén nephropathiák: a vékony bazális membrán nephropathiától az Alport-szindrómáig [Collagen type IV nephropathy: from thin basement membrane nephropathy to Alport syndrome]. Orv Hetil. 2005;146(52):2647–53.PubMed Endreffy E, Ondrik Z, Kemény E, et al. IV-es típusú kollagén nephropathiák: a vékony bazális membrán nephropathiától az Alport-szindrómáig [Collagen type IV nephropathy: from thin basement membrane nephropathy to Alport syndrome]. Orv Hetil. 2005;146(52):2647–53.PubMed
22.
go back to reference Flinter F. Alport Syndrome. In: The Genetics of Renal Disease. Oxford: Oxford University Press; 2004. p. 183–95. Flinter F. Alport Syndrome. In: The Genetics of Renal Disease. Oxford: Oxford University Press; 2004. p. 183–95.
Metadata
Title
An overview of the multi-pronged approach in the diagnosis of Alport syndrome for 22 children in Northeast China
Authors
Li Zhang
Bai-chao Sun
Bing-gang Zhao
Qing-shan Ma
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Nephrology / Issue 1/2020
Electronic ISSN: 1471-2369
DOI
https://doi.org/10.1186/s12882-020-01962-y

Other articles of this Issue 1/2020

BMC Nephrology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.